Prab at 18:41, 18 March 2025

2025-03-18T18:41:19Z

← Older revision		Revision as of 18:41, 18 March 2025
Line 75:		Line 75:
	[[Category:Anti-inflammatory agents]]		[[Category:Anti-inflammatory agents]]
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-17T17:18:27Z

CSV import

← Older revision		Revision as of 17:18, 17 March 2025
Line 75:		Line 75:
	[[Category:Anti-inflammatory agents]]		[[Category:Anti-inflammatory agents]]
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T22:28:36Z

CSV import

← Older revision		Revision as of 22:28, 10 February 2025
Line 74:		Line 74:
	[[Category:Immunosuppressants]]		[[Category:Immunosuppressants]]
	[[Category:Anti-inflammatory agents]]		[[Category:Anti-inflammatory agents]]
			{{No image}}

Prab: CSV import

2024-12-03T05:56:27Z

CSV import

New page

{{Infobox drug
| name = Levilimab
| image = 
| width =
| alt =
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_EU =
| DailyMedID =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| routes_of_administration =
| ATC_prefix =
| ATC_suffix =
| ATC_supplemental =
| legal_AU =
| legal_BR =
| legal_CA =
| legal_DE =
| legal_NZ =
| legal_UK =
| legal_US =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number =
| PubChem =
| DrugBank =
| ChemSpiderID =
| UNII =
| KEGG =
| ChEBI =
| ChEMBL =
| synonyms =
}}

'''Levilimab''' is a monoclonal antibody used in the treatment of various inflammatory conditions. It is specifically designed to target and inhibit the activity of interleukin-6 (IL-6), a cytokine involved in the inflammatory response. By blocking IL-6, levilimab can reduce inflammation and modulate the immune system's activity.

==Mechanism of Action==
Levilimab works by binding to the IL-6 receptor, preventing IL-6 from exerting its effects on target cells. IL-6 is a pro-inflammatory cytokine that plays a crucial role in the immune response, particularly in the activation of T-cells and the production of acute phase proteins by the liver. By inhibiting IL-6, levilimab can decrease the inflammatory response and is useful in treating conditions characterized by excessive inflammation.

==Clinical Uses==
Levilimab is primarily used in the treatment of autoimmune diseases and inflammatory conditions such as rheumatoid arthritis and cytokine release syndrome. It may also be investigated for use in other conditions where IL-6 plays a significant role in pathogenesis.

==Side Effects==
Common side effects of levilimab include injection site reactions, upper respiratory tract infections, and headaches. Serious side effects may include increased risk of infections due to immunosuppression, liver enzyme abnormalities, and gastrointestinal perforations.

==Pharmacokinetics==
Levilimab is administered via subcutaneous injection. It has a long half-life, allowing for less frequent dosing compared to some other biologics. The drug is metabolized through the reticuloendothelial system and is not significantly excreted through the kidneys or liver.

==Regulatory Status==
Levilimab is approved for use in several countries for specific indications. Its approval status may vary depending on the regulatory body and the specific condition being treated.

==Research and Development==
Ongoing research is exploring the use of levilimab in other inflammatory and autoimmune conditions. Clinical trials are assessing its efficacy and safety in broader patient populations.

==See Also==
* [[Interleukin-6]]
* [[Monoclonal antibody therapy]]
* [[Rheumatoid arthritis]]
* [[Cytokine release syndrome]]

{{Monoclonal antibodies}}
{{Immunosuppressive drugs}}

[[Category:Monoclonal antibodies]]
[[Category:Immunosuppressants]]
[[Category:Anti-inflammatory agents]]

Levilimab - Revision history

Prab at 18:41, 18 March 2025

Prab: CSV import

Prab: CSV import

Prab: CSV import